Skip to main navigation Skip to search Skip to main content

Pyrazinamide–isoniazid hybrid: synthesis optimisation, characterisation, and antituberculous activity

  • Rocio I. Ramirez Panti
  • , Christian M. Aliaga Paucar
  • , Fernando Grandez Arias
  • , Patricia Sheen Cortovaria
  • , Mirko Juan Zimic Peralta
  • , Yudith Cauna Orocollo
  • , Ana C. Valderrama Negron
  • Universidad Nacional de Ingeniería
  • Universidad Peruana Cayetano Heredia

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Over time, the effective resistance mechanisms to various first-and second-line drugs against the disease of tuberculosis make its treatment extremely difficult. This work presents a new approach to synthesizing a hybrid of antituberculosis medications: isoniazid (INH) and pyrazinamide (PZA). The synthesis was performed using ultrasound-assisted synthesis to obtain an overall yield of 70%, minimizing the reaction time from 7 to 1 h. The evaluation of the biological activity of the hybrid (compound 2) was tested using the tetrazolium microplate assay (TEMA), showing inhibition in the growth of Mycobacterium tuberculosis H37Rv at a concentration of 0.025 mM at pH 6.0 and 6.7.

Translated title of the contributionHíbrido pirazinamida-isoniacida: optimización de síntesis, caracterización y actividad antituberculosa
Original languageEnglish
Pages (from-to)16-23
Number of pages8
JournalRevista Colombiana de Quimica
Volume50
Issue number3
DOIs
StatePublished - 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • MIC
  • isoniazid
  • pyrazinamide
  • tuberculosis TEMA
  • ultrasound

Fingerprint

Dive into the research topics of 'Pyrazinamide–isoniazid hybrid: synthesis optimisation, characterisation, and antituberculous activity'. Together they form a unique fingerprint.

Cite this